Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. (October 2018)

• Record Type: Journal Article
• Authors: Fujimori, Koki; Ishikawa, Mitsuru; Otomo, Asako; Atsuta, Naoki; Nakamura, Ryoichi; Akiyama, Tetsuya; Hadano, Shinji; Aoki, Masashi; Saya, Hideyuki; Sobue, Gen; Okano, Hideyuki
• Is Part Of: Nature medicine. Volume 24:Number 10(2018)
• Page Start: 1579
• Page End: 1589
• Publication Date: 2018-10
• Subjects: Pathology, Molecular -- Periodicals; Molecular biology -- Periodicals; 610.724
• DOI: 10.1038/s41591-018-0140-5
• Languages: English
• ISSNs: 1078-8956

Abstract

Abstract Amyotrophic lateral sclerosis (ALS) is a heterogeneous motor neuron disease for which no effective treatment is available, despite decades of research intoSOD1 -mutant familial ALS (FALS). The majority of ALS patients have no familial history, making the modeling of sporadic ALS (SALS) essential to the development of ALS therapeutics. However, as mutations underlying ALS pathogenesis have not yet been identified, it remains difficult to establish useful models of SALS. Using induced pluripotent stem cell (iPSC) technology to generate stem and differentiated cells retaining the patients' full genetic information, we have established a large number of in vitro cellular models of SALS. These models showed phenotypic differences in their pattern of neuronal degeneration, types of abnormal protein aggregates, cell death mechanisms, and onset and progression of these phenotypes in vitro among cases. We therefore developed a system for case clustering capable of subdividing these heterogeneous SALS models by their in vitro characteristics. We further evaluated multiple-phenotype rescue of these subclassified SALS models using agents selected from non-SOD1 FALS models, and identified ropinirole as a potential therapeutic candidate. Integration of the datasets acquired in this study permitted the visualization of molecular pathologies shared across a wide range of SALS models. iPSC-derived motor neurons from over 30 heterogeneous sporadic ALS cases exhibit pathologies correlated with clinical disease progression, are more similar to FUS/TDP-43 familial ALS than SOD1-ALS and are corrected by repurposing of ropinirole.